The Global peptide therapeutics market was valued at $ 35.2 Billion in 2017 and is forecast to grow at a modest xx.6 % CAGR between 2018 and 2025, culminating in 2025 global sales of $ xx6.6 Billion. Signiant number of new peptides are entering into the market. 8 in 2012 to xx in 2018. Rising incidence of cancer and metabolic disorder pushing demand for biologic and biosimilars. Demand from developing countries pushing for low cost biosimilars. This ultimately increasing the demand for both innovative and generic peptides.
We are observing upswing due to recent advances in genomics with new targets identified for peptide therapy and safer compared to small molecule. Strong pipeline is also another factor driving the market. In addition, advancements in the processes of manufacturing peptides is expected to enhance further development of therapeutics.
End users need support at all stages from the peptide manufacturer such as from preclinical to commercialization. Peptide manufacturer having comprehensive GMP from milligrams to 100 KG and ability to provide services ranging from development, optimization and validation to scalable and economic process are going to lead the market.
“Optimal Price Point (OPP) for Global Peptide Therapeutics Products”
Estimated Average peptide product cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.
Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the Global, the peptide therapeutics products are available at USD XXXX. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products. The cost of a Peptide Therapeutics facility would be very high. At current prices, the capital cost might be expected to be in the range $XX-XX Million with the annual operating costs of the order of $1 Million.
We have segmented the market based on the application types such as Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, Pain and Dermatology. Cell-penetrating peptides (CPP) have served to deliver various molecules and particles into cells. Vaccine made up of peptides use tumor associated antigens to target cancer. Natriuretic peptides used as biomarkers for the purpose of personalized heart failure treatments and maintain heart pressure and volume, as well as regulating cardiovascular remodeling pathways.
Manufacturer Type Insight
We have segmented the market based on manufacturer type as Generic and Innovative. Innovative peptide dominating the market in terms of revenue and held a market share of 72%. However, demand for generic medicine from emerging countries will create demand for generic peptide. Recent loss of patents of many branded medicines will also create opportunity for generic peptides. Custom Peptide are also in demand and offers numerous options for synthesis platforms, purity levels, modifications, and formats to meet a variety of research needs.
Given the current state of technology for peptide synthesis and characterization, FDA believes it is now possible for an ANDA applicant to demonstrate that the active ingredient in a proposed generic synthetic peptide drug product (proposed generic synthetic peptide) is the “same” as the active ingredient in a previously approved peptide of rDNA origin.
Route of Administration-
We have segmented the market based on route of administration as parenteral, oral, pulmonary, mucosal and others. Parenteral route is the most commonly employed method of administration for therapeutic proteins and peptides. However, requirement of frequent injections due to short in vivo half-life results in poor patient compliance. Oral route offers the advantages of self-administration with a high degree of patient acceptability and compliance. Some of the distinct advantages of pulmonary route will be large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium.
Mucosal route (i.e., the mucosal linings of the nasal, rectal, vaginal, ocular and oral cavity) have distinct advantages such as possible bypass of the first pass effect, avoidance of pre-systemic elimination of gastrointestinal tract. A better enzymatic flora for drug absorption.
North America accounted for over xx% revenue share in 2017. The key reasons attributed for the high share include strong reimbursement framework, highly skilled medical professionals, technological advancements and government support for R&D and innovation in medical devices sector. Moreover, the presence of high-end therapeutic drugs and high emphasis on outcome is expected to boost the usage rates over the forecast period.
We have observed strong market during the years 2004-2012 with the development of new peptides and generics. Europe and is expected to grow during the forecast period with rising demand from Asian and South American markets.
Merger and Acquisition Insight
We are observing some unique merger and acquisition in this space. In 2017, Polypeptide Group announced acquisition of the peptides business and operations of Lonza in Belgium. Bachem is planning to acquire a mid-size peptide manufacturer in Europe in recent time.
Top Players & Company Share
We have profiled major players in the market as Bachem Holding AG, Eli Lilly and Company, Pfizer Inc., Amgen Inc., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical, Lonza Inc., Sanofi, Bristol-Myers Squibb(BMS), AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, Novo Nordisk A/S, PolyPeptide Laboratories. With recent development in technology, we are observing some unique new players into the market.
GLOBAL Peptide Therapeutics Market by Application Types (Revenue, USD Million, 2014- 2025)
- Cardiovascular Disorder
- Metabolic Disorder
- Respiratory Disorder
GLOBAL Peptide Therapeutics Market by Approval Status (Revenue, USD Million, 2014 – 2025)
GLOBAL Peptide Therapeutics Market by Manufacturer Type (Revenue, USD Million, 2014- 2025)
GLOBAL Peptide Therapeutics Market by Route of Administration (Revenue, USD Million, 2014- 2025)
GLOBAL Peptide Therapeutics Systems Regional Outlook (Revenue, USD Million, 2014- 2025)
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia